

Takeda – Withdrawal of Vonvendi[®] (von Willebrand factor, recombinant)

- On January 26, 2024, <u>Takeda announced</u> a consumer level withdrawal of two lots of <u>Vonvendi</u> (von Willebrand factor, recombinant) because of misprinted product labels with an incorrect expiration date.
- There is no quality issue with Vonvendi. The safety and efficacy profile remains consistent with the labeled information. The expiration date on the outside of the package (June 27, 2025) is six months after the actual expiration date (January 27, 2025).
- The withdrawn lots are listed below:

Product Description	NDC number	Lot number (Exp Date)
Vonvendi (von Willebrand factor, recombinant), 650 IU	0944-7550-01, 0944-7551-02, 0944-7553-02	TVA22004AA (6/27/2025); TVA22004AB (6/27/2025)

- Vonvendi is indicated for use in adults diagnosed with von Willebrand disease (VWD) for ondemand treatment and control of bleeding episodes, perioperative management of bleeding, routine prophylaxis to reduce frequency of bleeding episodes in patients with severe Type 3 VWD receiving on-demand therapy.
- Anyone with the affected products on hand should discontinue use, stop distribution and quarantine product immediately. Patients with impacted product on hand should return to their pharmacy for a replacement.
- Patients should contact their healthcare provider if they have experienced any problems that may be related to using the withdrawn products.
- Consumers may contact Takeda at 1-877-825-3327 for more information.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews[®] is published by the Optum Rx Clinical Services Department.